## Building the Future With Our Partners

Two Locations. One Approach. One Agilent.

## Building on our success

- State of the art equipment trains
- World class analytical services
- Consistent approach to process development and scale-up


Boulder, Colorado


Frederick, Colorado

Agilent's Boulder and Frederick, Colorado manufacturing sites are U.S. Food \& Drug Administration (FDA) inspected facilities and our business is accredited as a foreign manufacturer for non-sterile drugs by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
www.agilent.com/chem/nucleicacid pdl-boulderinfo@agilent.com

This information is subject to change without notice.

## PR7000-2460

© Agilent Technologies, Inc. 2020
Published in the USA, April, 2020
5991-9355EN

Partner with Agilent's Nucleic Acid Solutions Division and benefit from our industry leading experience. Efficiently advance your lead oligo candidates from clinic to market with a common goal of patient health and safety. Our Colorado manufacturing sites provide:

Purpose-built facilities for nucleic-acid-based therapeutics

- Two facilities and more than 300 employees
- Over 200,000 square feet of cGMP space
- Future expansion design in progress


## Full-service CDMO

- Analytical and process development and validation
- Multiple suites to enable the simultaneous manufacture of several products
- Commitment to cGMP compliance
- In-house stability for API and drug product
- Dedicated Project Managers and Product Quality Engineers

Collaboration

- Accelerate speed to clinic and scale-up via an efficient chemical development approach
- Enables cost-effective manufacturing of commercial-scale quantities
- Provides superior product quality
- Gives unparalleled commitment to world-class innovation


## Continuing to break new ground in nucleic acid therapeutics manufacturing

When your next clinical trial or patient's wellbeing depends on API availability, assurance of supply is a top priority.

Put your trust in Agilent to meet your clinical and commercial needs.

